Johnson & Johnson Price to Book Ratio 2012-2026 | JNJ
Historical price to book ratio values for Johnson & Johnson (JNJ) over the last 10 years. The current price to book ratio for Johnson & Johnson as of June 12, 2026 is 7.05.
| Johnson & Johnson Price/Book Ratio Historical Data | |||
|---|---|---|---|
| Date | Stock Price | Book Value per Share | Price to Book Ratio |
| 2026-06-12 | 240.87 | 7.11 | |
| 2025-12-31 | 204.66 | $33.86 | 6.04 |
| 2025-09-30 | 182.21 | $32.95 | 5.53 |
| 2025-06-30 | 149.01 | $32.61 | 4.57 |
| 2025-03-31 | 160.41 | $32.47 | 4.94 |
| 2024-12-31 | 138.77 | $29.70 | 4.67 |
| 2024-09-30 | 154.27 | $29.14 | 5.29 |
| 2024-06-30 | 138.09 | $29.72 | 4.65 |
| 2024-03-31 | 148.25 | $29.09 | 5.10 |
| 2023-12-31 | 145.79 | $28.57 | 5.10 |
| 2023-09-30 | 143.72 | $29.59 | 4.86 |
| 2023-06-30 | 151.63 | $29.41 | 5.16 |
| 2023-03-31 | 140.93 | $27.27 | 5.17 |
| 2022-12-31 | 159.47 | $29.39 | 5.43 |
| 2022-09-30 | 146.52 | $28.51 | 5.14 |
| 2022-06-30 | 158.15 | $29.04 | 5.45 |
| 2022-03-31 | 156.90 | $28.41 | 5.52 |
| 2021-12-31 | 150.48 | $28.16 | 5.34 |
| 2021-09-30 | 141.13 | $26.69 | 5.29 |
| 2021-06-30 | 143.11 | $26.44 | 5.41 |
| 2021-03-31 | 141.89 | $25.01 | 5.67 |
| 2020-12-31 | 135.03 | $24.04 | 5.62 |
| 2020-09-30 | 126.86 | $24.49 | 5.18 |
| 2020-06-30 | 119.04 | $23.92 | 4.98 |
| 2020-03-31 | 110.23 | $23.28 | 4.73 |
| 2019-12-31 | 121.84 | $22.59 | 5.39 |
| 2019-09-30 | 107.33 | $22.13 | 4.85 |
| 2019-06-30 | 114.68 | $23.01 | 4.98 |
| 2019-03-31 | 114.32 | $22.20 | 5.15 |
| 2018-12-31 | 104.84 | $22.44 | 4.67 |
| 2018-09-30 | 111.54 | $24.09 | 4.63 |
| 2018-06-30 | 97.30 | $23.45 | 4.15 |
| 2018-03-31 | 102.01 | $23.58 | 4.33 |
| 2017-12-31 | 110.51 | $22.43 | 4.93 |
| 2017-09-30 | 102.20 | $27.55 | 3.71 |
| 2017-06-30 | 103.34 | $26.78 | 3.86 |
| 2017-03-31 | 96.65 | $26.10 | 3.70 |
| 2016-12-31 | 88.82 | $26.02 | 3.41 |
| 2016-09-30 | 90.44 | $26.73 | 3.38 |
| 2016-06-30 | 92.25 | $26.47 | 3.48 |
| 2016-03-31 | 81.71 | $26.40 | 3.09 |
| 2015-12-31 | 77.01 | $25.82 | 2.98 |
| 2015-09-30 | 69.47 | $25.86 | 2.69 |
| 2015-06-30 | 71.98 | $25.69 | 2.80 |
| 2015-03-31 | 73.76 | $24.45 | 3.02 |
| 2014-12-31 | 76.14 | $25.06 | 3.04 |
| 2014-09-30 | 77.11 | $27.31 | 2.82 |
| 2014-06-30 | 75.18 | $27.65 | 2.72 |
| 2014-03-31 | 70.10 | $27.08 | 2.59 |
| 2013-12-31 | 64.89 | $26.25 | 2.47 |
| 2013-09-30 | 60.99 | $24.75 | 2.46 |
| 2013-06-30 | 59.96 | $24.75 | 2.42 |
| 2013-03-31 | 56.51 | $23.85 | 2.37 |
| 2012-12-31 | 48.20 | $23.33 | 2.07 |
| 2012-09-30 | 46.97 | $23.08 | 2.03 |
| 2012-06-30 | 45.63 | $21.97 | 2.08 |
| 2012-03-31 | 44.12 | $22.35 | 1.97 |
| 2011-12-31 | 43.48 | $20.95 | 2.08 |
| 2011-09-30 | 41.84 | $22.52 | 1.86 |
| 2011-06-30 | 43.32 | $22.67 | 1.91 |
| 2011-03-31 | 38.25 | $21.86 | 1.75 |
| 2010-12-31 | 39.57 | $20.66 | 1.92 |
| 2010-09-30 | 39.30 | $20.85 | 1.88 |
| 2010-06-30 | 37.11 | $19.19 | 1.93 |
| 2010-03-31 | 40.60 | $19.19 | 2.12 |
| 2009-12-31 | 39.80 | $18.37 | 2.17 |
| 2009-09-30 | 37.33 | $18.27 | 2.04 |
| 2009-06-30 | 34.55 | $16.79 | 2.06 |
| 2009-03-31 | 31.71 | $15.87 | 2.00 |
| 2008-12-31 | 35.77 | $15.35 | 2.33 |
| 2008-09-30 | 41.08 | $16.45 | 2.50 |
| 2008-06-30 | 37.91 | $16.61 | 2.28 |
| 2008-03-31 | 37.95 | $16.19 | 2.34 |
| 2007-12-31 | 38.76 | $15.25 | 2.54 |
| 2007-09-30 | 37.95 | $15.17 | 2.50 |
| 2007-06-30 | 35.35 | $14.90 | 2.37 |
| 2007-03-31 | 34.35 | $14.14 | 2.43 |
| 2006-12-31 | 37.41 | $13.59 | 2.75 |
| 2006-09-30 | 36.59 | $13.97 | 2.62 |
| 2006-06-30 | 33.57 | $13.89 | 2.42 |
| 2006-03-31 | 32.97 | $13.83 | 2.38 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Large Cap Pharmaceutical | $574.358B | $94.193B |
| Johnson & Johnson's biggest strength is its diversified business model. It operates through pharmaceuticals, medical devices and consumer products divisions. Its diversification helps it to withstand economic cycles more effectively. J&J has one of the largest research and development (R&D) budget among pharma companies. J&J's worldwide business is divided into three segments: Pharmaceutical, Medical Devices and Consumer. The company has several drugs covering a broad range of areas such as neuroscience, cardiovascular & metabolism, immunology, oncology, pulmonary hypertension and infectious diseases and vaccines. The Medical Devices Segment offers products in the orthopedics, surgery, interventional solutions and vision markets. The Consumer Segment segment includes a broad range of products covering the areas of baby care, beauty/skin health, oral care, wound care and womens' health care, as well as over-the-counter (OTC) pharmaceutical products. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eli Lilly (LLY) | United States | $887.629B | 38.81 |
| AbbVie (ABBV) | United States | $367.673B | 20.79 |
| Roche Holding AG (RHHBY) | Switzerland | $318.782B | 0.00 |
| Merck (MRK) | United States | $299.893B | 13.54 |
| Novartis AG (NVS) | Switzerland | $293.951B | 17.16 |
| Novo Nordisk (NVO) | Denmark | $167.527B | 9.60 |
| Pfizer (PFE) | United States | $153.074B | 8.33 |
| Sanofi (SNY) | France | $114.048B | 10.56 |
| Bayer (BAYRY) | Germany | $46.178B | 8.70 |
| Innoviva (INVA) | United States | $1.760B | 5.88 |